Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/173828
Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Background: There is no randomized clinical trials with recurrence of atherosclerotic cardiovascular disease (ASCVD) as a major outcome with rosuvastatin. In order to analyze potential differences in the clinical response to atorvastatin and rosuvastatin in secondary ASCVD prevention, we have analyzed the clinical evolution of those subjects of the Dyslipemia Registry of the Spanish Society of Arteriosclerosis (SEA) who at the time of inclusion in the Registry had already suffered an ASCVD. Methods: This observational, retrospective, multicenter, national study was designed to determine potential differences between the use of atorvastatin and rosuvastatin in the ASCVD recurrence. Three different follow-up start-times were performed: time of inclusion in the registry; time of first event if this occurred after 2005, and time of first event without date restriction. Results: Baseline characteristics were similar between treatment groups. Among atorvastatin or rosuvastatin users, 89 recurrences of ASCVD were recorded (21.9%), of which 85.4% were coronary. At the inclusion of the subject in the registry, 345 participants had not suffered a recurrence yet. These 345 subjects accumulated 1050 person-years in a mean follow-up of 3 years. Event rates were 2.73 (95% CI: 1.63, 4.25) cases/100 person-years and 2.34 (95% CI: 1.17, 4.10) cases/100 person-years in the atorvastatin and rosuvastatin groups, respectively. There were no statistically significant differences between the two groups independently of the follow-up start-time. Conclusions: This study does not find differences between high doses of rosuvastatin and atorvastatin in the recurrence of ASCVD, and supports their use as clinically equivalent in secondary prevention of ASCVD.
Matèries
Matèries (anglès)
Citació
Citació
PÉREZ CALAHORRA, Sofía, LACLAUSTRA, Martín, MARCO BENEDI, Victoria, PINTÓ SALA, Xavier, SÁNCHEZ HERNÁNDEZ, Rosa m., PLANA, Núria, ORTEGA MARTÍNEZ DE VICTORIA, Emilio, FUENTES, Francisco, CIVEIRA, Fernando. Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence. _Lipids in Health and Disease_. 2019. Vol. 18. [consulta: 24 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/173828]